BioSpace News Archive

Pharm Country

RYBREVANT® (amivantamab-vmjw) Provides Higher Activity and Longer Duration of Response When Used in Combination with Lazertinib in Patients with Advanced EGFR-Mutant Non-Small Cell Lung Cancer Who Have Failed Osimertinib

The Janssen Pharmaceutical Companies of Johnson & Johnson announced a new analysis from the CHRYSALIS study evaluating RYBREVANT® monotherapy and a combination regimen with lazertinib in advanced non-small cell lung cancer patients with epidermal growth factor receptor mutations who progressed after osimertinib.

September 19, 2021
·
19 min read
Drug Development

New Data on RYBREVANT® (amivantamab-vmjw) in Combination with Lazertinib Show Early Activity in Patients with Non-Small Cell Lung Cancer Whose Disease Has Progressed After Both Osimertinib and Platinum-Based Chemotherapy

The Janssen Pharmaceutical Companies of Johnson & Johnson announced preliminary results from the Phase 1b CHRYSALIS-2 study evaluating RYBREVANT® in combination with lazertinib in the treatment of patients with non-small cell lung cancer characterized by epidermal growth factor receptor exon 19 deletion or L858R mutations whose disease had progressed after treatment with osimertinib and platinum chemotherapy.

September 19, 2021
·
20 min read
Drug Development

Datopotamab Deruxtecan Shows Encouraging Tumor Response in Patients with Advanced Non-Small Cell Lung Cancer with Actionable Genomic Alterations

New data for datopotamab deruxtecan, a TROP2 directed DXd antibody drug conjugate being developed by Daiichi Sankyo Company, Limited and AstraZeneca, show an encouraging tumor response rate in patients with advanced non-small cell lung cancer with actionable genomic alterations.

September 19, 2021
·
10 min read
Biotech Beach

Sorrento Announces an Independent Real-World Study That Reports Superior Sensitivity Results in Detecting COVID-19 Virus Infections in All-Comer General Population by COVISTIX as Compared to a Globally Leading Rapid Antigen Test

Sorrento Therapeutics, Inc., a clinical and commercial stage biopharmaceutical company developing new therapies to treat cancer, pain, autoimmune disease and COVID-19, announced impressive results from an independent study conducted under real-world field conditions by INMEGEN.

September 19, 2021
·
5 min read
Pharm Country

HUTCHMED Initiates a Japan Bridging Study to Support Surufatinib Registration for Advanced Neuroendocrine Tumors

HUTCHMED Limited announces that it has initiated a Japan registration-enabling bridging study for surufatinib to support the registration of surufatinib in the treatment of patients with advanced neuroendocrine tumors.

September 19, 2021
·
9 min read